LRRK2 inhibitor Halia Therapeutics

N/A

Report date: 2025/03/20 15:13:33

Base Information

Drug NameLRRK2 inhibitor Halia Therapeutics
Drug Alias NameN/A
ClassificationOther
Mechanisms of ActionLeucine-rich repeat serine/threonine-protein kinase 2 inhibitors
TargetsLeucine-rich repeat serine/threonine-protein kinase 2
Therapy Area/IndicationsParkinson Disease
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited States
CombinationsNo
Global Highest StatusPreclinical
Highest Status in ChinaN/A
Originator CompaniesHalia Therapeutics Inc
China Registration ClassN/A

Develop Information

Active CompaniesHalia Therapeutics Inc
Inactive CompaniesN/A
Active IndicationsParkinson Disease
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A